- Home
- CNMD vs CNTA Comparison
CNMD vs CNTA Comparison
Compare CNMD & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNMD
- CNTA
- Stock Information
- Founded
- CNMD 1970
- CNTA 2020
- Country
- CNMD United States
- CNTA United Kingdom
- Employees
- CNMD N/A
- CNTA N/A
- Industry
- CNMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- CNMD Health Care
- CNTA Health Care
- Exchange
- CNMD Nasdaq
- CNTA Nasdaq
- Market Cap
- CNMD 1.7B
- CNTA 1.9B
- IPO Year
- CNMD 1987
- CNTA 2021
- Fundamental
- Price
- CNMD $47.62
- CNTA $15.69
- Analyst Decision
- CNMD Hold
- CNTA Strong Buy
- Analyst Count
- CNMD 5
- CNTA 10
- Target Price
- CNMD $62.20
- CNTA $28.78
- AVG Volume (30 Days)
- CNMD 421.5K
- CNTA 984.4K
- Earning Date
- CNMD 07-30-2025
- CNTA 08-12-2025
- Dividend Yield
- CNMD 1.67%
- CNTA N/A
- EPS Growth
- CNMD 46.38
- CNTA N/A
- EPS
- CNMD 3.81
- CNTA N/A
- Revenue
- CNMD $1,315,998,000.00
- CNTA $15,000,000.00
- Revenue This Year
- CNMD $6.27
- CNTA N/A
- Revenue Next Year
- CNMD $5.62
- CNTA N/A
- P/E Ratio
- CNMD $12.55
- CNTA N/A
- Revenue Growth
- CNMD 4.32
- CNTA 118.88
- 52 Week Low
- CNMD $46.00
- CNTA $9.00
- 52 Week High
- CNMD $78.19
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- CNMD 32.15
- CNTA 68.00
- Support Level
- CNMD $48.52
- CNTA $13.22
- Resistance Level
- CNMD $50.50
- CNTA $15.48
- Average True Range (ATR)
- CNMD 1.97
- CNTA 0.70
- MACD
- CNMD -0.38
- CNTA 0.21
- Stochastic Oscillator
- CNMD 1.16
- CNTA 86.44
About CNMD CONMED Corporation
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.